Navigation Links
Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods
Date:11/20/2008

CAMBRIDGE, England, November 20 /PRNewswire-FirstCall/ -- Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, has signed a Master Service Agreement of up to five years with Pfizer Limited, the UK operating unit of the global research-based pharmaceutical company Pfizer, Inc. (NYSE: PFE). Under the terms of the agreement, SCS will provide research services, cell lines, media and reagents to support Pfizer's R&D efforts in this important field.

Dr Alastair Riddell, CEO of SCS, said, "The opening of Pfizer's new regenerative medicine research facility in Cambridge, UK, last week is very important for stem cell research and reinforces the UK's position as an international centre of excellence. We are therefore very pleased to be able to support Pfizer's efforts to advance biomedical research under our new agreement."

The Pfizer regenerative medicine unit will be led by Chief Scientific Officer, Ruth McKernan, PhD, who said, "I'm very excited to lead this new research unit. While there is still a lot to understand about how stem cells can be used therapeutically, we believe it is one of the most promising areas of scientific research. Building successful partnerships with companies such as Stem Cell Sciences will be important for us."

About Stem Cell Sciences plc

Stem Cell Sciences (SCS) is an international research and development company focusing on the commercial application of stem cell biology technologies for drug discovery and regenerative medicine research. Stem Cell Sciences is now focussing on building revenues through the sale of products, collaborative research and licensing deals with international biotechnology and pharmaceutical companies.

Stem Cell Sciences has a substantial portfolio of patents and patent applications in both adult and embryonic stem cell fields. The Company has been active in the stem cell research field since 1994, principally focused on technologies to grow, differentiate, and purify adult and embryonic stem cells. These include technologies to permit the generation of highly purified stem cells and their differentiated progeny (specialised tissue cell types) for use in genetic, pharmacological and toxicological screens. Moreover, these technologies may be able to provide pure populations of appropriate cell types for transplantation therapies in the future.

The Company has its main research base and headquarters in Cambridge, UK with a second research base in Monash near Melbourne, Australia and a business development office in San Francisco, USA.

For further information on the company please visit: http://www.stemcellsciences.com.

    For further information, please contact:

    Stem Cell Sciences plc (United Kingdom),
    Alastair Riddell, CEO,
    Tim Allsopp, Chief Scientific Officer,
    +44(0)1223-499160;

    Stem Cell Sciences pty ltd (Australia),
    Paul Bello, Operations Manager,
    +61(0)400-500-495;

    Citigate Dewe Rogerson (For SCS, UK),
    Mark Swallow / Emma Palmer Foster / Amber Bielecka,
    +44(0)20-7638-9571;

    Talk Biotech (For SCS, Australia),
    Fay Weston, Director,
    +61(0)422-206-036;

    Daniel Stewart & Company (NOMAD to SCS, UK),
    Simon Leathers / Simon Starr,
    +44(0)207-776-6566


'/>"/>
SOURCE Stem Cell Sciences plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
2. BBM Announces Offer to Acquire YM BioSciences Inc.
3. Human Pheromone Sciences Announces Third Quarter Results
4. Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
5. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
6. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
7. Stem Cell Sciences Enters into Services Agreement with Huntingdons Disease Research Group, CHDI Foundation Inc.
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
9. Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
10. Advanced Life Sciences Announces Third Quarter 2008 Financial Results
11. LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... $7M Series B financing, adding an additional $3M from ... by Mesa Verde Venture Partners and other strategic partners ... directed towards further accelerating commercial adoption of their flagship ... test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
Breaking Biology Technology:
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):